Finally, Fujino struck gold, with one of Japan's first-ever, truly original, global bestselling pharmaceuticals.
Fujino worked 365 days a year for over a decade to perfect his medicine.
Within a year Fujino was producing kilograms of LHRH and TRH (thyrotropin-releasing hormone) with crystal purity.
Despite the blockbusters and his rise to chairman, Fujino's real legacy is the research institute he created.
Fujino realized LHRH would make a perfect treatment for prostate and breast cancer.
Returning to Takeda in 1969, Fujino concentrated on finding a better way of synthesizing the hormones being discovered by the two teams.
Takeda has announced the discovery of 13 of these keys, as well as 6 previously unknown receptors, and has more it has not announced yet, Fujino says.
After one year Fujino felt he had nothing more to learn there and got himself a fully paid scholarship to study biochemistry at the University of Texas.
If you find a key that changes basic functions of a cell and make substances that mimic these keys and locks, interesting new drugs are sure to emerge, Fujino thought.
After years of painstaking work and much trial and error, Fujino and fellow researchers discovered a way of putting the medicine inside microcapsules made of the same material as surgical thread.
As a part of Guillemin's team Fujino was made a distinguished alumnus of the University of Texas for discovering that one of these key proteins, LHRH (luteinizing hormone-releasing hormone), consisted of two loosely linked proteins, a new type of structure.
应用推荐